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Lizzy M Brewster1* and Yackoob K Seedat2Abstract
Background: Clinicians are encouraged to take an individualized approach when treating hypertension in patients
of African ancestry, but little is known about why the individual patient may respond well to calcium blockers and
diuretics, but generally has an attenuated response to drugs inhibiting the renin-angiotensin system and to
β-adrenergic blockers. Therefore, we systematically reviewed the factors associated with the differential drug
response of patients of African ancestry to antihypertensive drug therapy.
Methods: Using the methodology of the systematic reviews narrative synthesis approach, we sought for published
or unpublished studies that could explain the differential clinical efficacy of antihypertensive drugs in patients of
African ancestry. PUBMED, EMBASE, LILACS, African Index Medicus and the Food and Drug Administration and
European Medicines Agency databases were searched without language restriction from their inception through
June 2012.
Results: We retrieved 3,763 papers, and included 72 reports that mainly considered the 4 major classes of
antihypertensive drugs, calcium blockers, diuretics, drugs that interfere with the renin-angiotensin system and
β-adrenergic blockers. Pharmacokinetics, plasma renin and genetic polymorphisms did not well predict the
response of patients of African ancestry to antihypertensive drugs. An emerging view that low nitric oxide and high
creatine kinase may explain individual responses to antihypertensive drugs unites previous observations, but
currently clinical data are very limited.
Conclusion: Available data are inconclusive regarding why patients of African ancestry display the typical response
to antihypertensive drugs. In lieu of biochemical or pharmacogenomic parameters, self-defined African ancestry
seems the best available predictor of individual responses to antihypertensive drugs.
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There is a great need for individual treatment options
in hypertensive patients of African ethno-geographical
ancestry [1-5]. Compared with hypertension in other
population subgroups, the disorder in these patients
is often more severe, more resistant to treatment, and
leads to earlier end organ damage and premature death* Correspondence: l.m.brewster@amc.uva.nl
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distribution, and reproduction in any medium[1-4]. Thus, hypertension seems to be a more aggressive
disease in patients of African ancestry. This has impor-
tant implications for the choice of an antihypertensive
agent [3,5].
Antihypertensive drugs were the first cardiovascular
therapy for which there was wide recognition of diffe-
rences in clinical efficacy related to ethno-geographical
ancestry [6]. Patients of African ancestry as a group re-
spond better to calcium blockers and diuretics, while the
response to β-adrenergic blockade and inhibition of the
angiotensin converting enzyme is attenuated (Table 1)Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Differences in clinical efficacy of antihypertensive drugs in ancestry groups
Systolic/diastolic blood pressure reduction*
Drug category European ancestry African ancestry Difference†
Calcium blockers 15.3/12.6 16.9/13.3 2.4/0.6
(14.7, 15.9)/(12.3, 12.9) (16.0, 17.7)/(12.9, 13.8) (3.4, 1.3)/(1.2, 0.0)
Diuretics 11.5/9.1 15.0/10.7 3.5/1.5
(9.5, 13.4)/(8.1, 10.1) (13.1, 17.0)/(9.5, 11.9) (6.4, 0.5)/(3.1, −0.1)
ACE-i 12.8/11.4 8.5/8.0 −4.6/−3.0
(11.7, 13.9)/(10.8, 12.0) (7.0, 9.9)/(7.1, 8.9) (−2.7, −6.5)/(−1.9, −4.1)
β-Blockers 11.7/11.3 5.9/9.5 −6.0/−2.9
(10.2, 13.3)/(10.5, 12.1) (4.2, 7.6)/(8.5, 10.4) (−3.6, −8.3)/(−1.6,−4.2)
Legend: Data depicted are pooled estimates (95% confidence intervals) from systematic reviews [3,7]. ACE-i, angiotensin converting enzyme inhibitors.
*Mean blood pressure reduction (mm Hg). †The depicted difference is the weighted pooled difference in response between ancestry groups, with positive values
indicating a greater response in patients of African ancestry and negative values indicating a greater response in patients of European ancestry.
Table 2 Factors that may affect the differential drug
response of patients of African ancestry
Category Factors
Environmental Diet (sodium) [2]
Bioavailability Absorption, First pass metabolism (intestinal
and phase 1 drug metabolism, polymorphisms
cytochrome P450 enzymes, phase 2 drug
metabolism) [6,9]
Distribution Protein binding, distribution volume
Receptor Receptor sensitivity and genetic variation [6,9]
Hemodynamics Low renin, sodium-volume dependent
hypertension [2]
Intracellular effects Nitric oxide, cGMP, cAMP, calcium fluxes, ion
transport, rho kinase, creatine kinase, myosin
light chain kinase, myosin ATPase [10-12]
Elimination Kidney, liver or other route
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variation in this response [7,8].
Greater knowledge about the potential causes for these
differences might lead to more individualized treatment
regimens, but to our knowledge, no previous study has
systematically addressed why patients of African ances-
try may have this specific pattern of responses. The aim
of this paper is to provide a systematic overview of the
factors associated with the differential drug response of
patients of African ancestry to antihypertensive drug
therapy.
Methods
We sought to identify all published or unpublished studies
that considered potential explanations for the differential
clinical efficacy of different classes of antihypertensive
drugs, used as single drug or single drug-based treatment
in non-pregnant adults of sub-Saharan African descent
with uncomplicated hypertension, defined as the absence
of reported clinical heart failure, current stroke or end
stage renal disease.
We first identified potential causes for differences in
specific drug responses based on ethno-geographic ori-
gin (Table 2). As we sought to explain differential blood
pressure lowering responses to different types of antihy-
pertensive drugs, we excluded general factors such as ac-
cess to care and differences in socio-economic status. To
answer the clinical question, why there was a difference
in response between people of African vs European an-
cestry, we considered pharmacokinetic variations in-
cluding polymorphisms in cytochrome P450 family of
enzymes involved in phase I drug metabolism, and po-
lymorphisms in genes encoding enzymes involved in
phase II drug metabolism. Furthermore, we considered
genetic polymorphisms that may influence pharmaco-
dynamics including alpha-adducin (ADD1), subunits of
G-proteins (GNB3 and GNAS1), the β-1-adrenergic recep-
tor (ADRB1), endothelial nitric oxide synthase (NOS3),and components of the renin-angiotensin-aldosterone
(RAAS) system, angiotensinogen (AGT), renin (REN), an-
giotensin converting enzyme (ACE), the angiotensin II re-
ceptor type I (AGTR1 or AT1R), and aldosterone synthase
(CYP11B2) [9]. Finally, hypertension in persons of African
ancestry is characterized by high vascular contractility,
greater salt sensitivity and, in general, low plasma renin
activity [2], and the molecular basis of these changes has
been related to low nitric oxide (NO) bioavailability [10],
to the activity of Ca2+ATPase, myosin ATPase, Na+K+
ATPase, and to the central regulatory enzyme of energy
metabolism, creatine kinase (CK), which rapidly regener-
ates adenosine triphosphate (ATP) from phosphocreatine
near these ATPases [11,12].
Using these environmental, pharmacokinetic, pharma-
codynamic and pharmacogenomic factors, we conducted
a systematic literature search in electronic databases,
including PUBMED, EMBASE, LILACS (Literatura
Latino-Americana y del Caribe en Ciencias de la Salud),
the African Index Medicus (AIM), and the Food and Drug
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(EMA) databases, dated June 2012.
We developed a search strategy to find papers that
considered causes for differential responses, rather than
finding clinical trials per se [3]. To reach this end, the
most effective strategy in terms of the yield in eligible
papers was to not include drug names, or “hyperten-
sion”, but the factors as mentioned in Table 2, using the
following keywords: “(salt OR pharmacokinetic OR re-
sorption OR bioavailability OR liver OR first pass OR
metabolism OR cytochrome OR n-acetyltransferase OR
catechol-o-methyltransferase OR phenol sulfotransferase
OR distribution OR protein binding OR elimination OR
pharmacodynamic OR pharmacogenetic OR receptor
OR G-protein OR alpha-adducin OR nitric oxide OR c-
GMP OR cAMP OR sarcoendoplasmic OR calcium OR
ion OR creatine kinase OR rho kinase OR “myosine
ATPase” OR “myosin light chain kinase”) and (black*
OR Afr* OR Creole OR Carribean OR Caribbean OR
negr* OR ethnic*) and antihypertensive.”
Finally, we hand-searched for studies by using electro-
nic cross referencing (“related citations”) from PUBMED,
references from textbooks, narrative reviews and system-
atic reviews; by contacting experts; and by searching the
Internet. We did not restrict the searches to any specific
language.
To produce a rigorously conducted narrative syste-
matic review, we used the “narrative synthesis approach”
(the PRISMA guideline is not designed for narrative
systematic reviews) [13]. This recently developed metho-
dology is applied when one expects considerable hetero-
geneity among the studies of interest. Distinctively, a
narrative rather than a statistical summary of the fin-
dings of studies is used to perform the data synthesis,
which yields a more detailed analysis of heterogeneous
data with less loss of information [13].
Any experimental research that is reported in the
manuscript has been performed with the approval of an
appropriate ethics committee. Research carried out on
humans were in compliance with the Helsinki Declaration,




We retrieved 2,520 citations in PUBMED, 1,002 in
EMBASE, 4 in LILACS, 2 in the AIM, 2 in the FDA and
229 in the EMA database for a total of 3,759 citations.
Four citations in the EMA database contained 2 clus-
tered reports, adding 4 papers to yield a total of 3,763
papers. After removing duplicate reports and applying
the inclusion criteria, 55 papers were included from the
electronic searches (please see Paper Flow, Figure 1, with
detailed mention of the reason for exclusion) [14-68].EMBASE, LILACS, AIM and the FDA database did not
yield any additional included reports beyond the papers
included from PUBMED, but one additional paper was
included from the EMA database [68]. The majority of
the excluded reports did not provide an explanation for
differences in antihypertensive drug response related to
ancestry. Hand search yielded 17 more papers [12,69-84],
most of which had no ancestry/ethnicity/race tag in
PUBMED, or were not indexed, such that these could
not be retrieved with electronic searches. We did not
use language restriction, but all included papers were
written in the English language.Description of included studies
The included studies were original reports that provided,
or attempted to provide, an explanation for the diffe-
rences in antihypertensive drug responses between hy-
pertensive patients of African and European ancestry.
The design of the included studies varied, from obser-
vational studies to small and large scale clinical trials,
in subjects of sub-Saharan African descent, studied
within Africa (Nigeria [46,59,67], Kenya [64], and South
Africa [26,61,62,69,78]), or in the African diaspora (the
Netherlands, persons from Suriname, the Dutch Antilles,
and Ghana [12,72,73]; United Kingdom, persons from
Nigeria [54,60], Sierra Leone [54], Zimbabwe [54],
Zambia [54], Tanzania [54], or country of origin not
stated [50]; all other were in the United States, except
for one paper that did not state the location of the study
[34]). Ethno-geographic origin was either self-defined, or
defined by the authors of the reports, in the participants
being of European or African ancestry. Authors used dif-
ferent nomenclature for African descent, including black
people, blacks, black race, black skinned people, African-
Americans and Afro-Caribbeans; as well as for European
descent, including white and Caucasian. We unified this
to: ‘persons (or patients) of African ancestry’ versus
‘European ancestry’, throughout this paper, as this no-
menclature captures concepts of genomic variation, biol-
ogy or geographic history [85]. The majority of papers
retrieved considered the four major classes of antihyper-
tensive drugs: calcium blockers, diuretics, drugs that
interfere with the renin-angiotensin-aldosterone system,
and β-adrenergic blockers (Table 3). Data are synthe-
sized below [13].Narrative synthesis
Calcium blockers
Clinical efficacy Calcium blockers are with diuretics
among the most effective classes of drugs to reduce
blood pressure in patients of African ancestry [3,7]. This
drug type remains effective in all subgroups of sex, age
and blood pressure strata, including high baseline diastolic




Excluded reports (n = 3,690)*
Not fulfilling main inclusion criteria
(n = 2,644)
Not considering causes for differences in 
drug response based on ancestry
(n = 982)
Double entry of a paper within one database 
(n = 63) 
Double publication
(n = 1)
Included                                                 
n = 55
Not included (n = 18)                                              
Not providing separate numerical data on 
different drug types 
(n = 2) 
No subgroup analyses based on ancestry
(n = 5)
Double publication
(n = 1) 
Duplicate eligible reports 
(n = 10)
Total included reports                               
n = 72
Non-electronic search 
contact with authors, hand searching
(n = 17) 
Figure 1 Flow diagram. Data were retrieved from PUBMED, EMBASE, LILACS, the African Index Medicus, and the Food and Drug Administration
and European Medicines Agency databases. *Studies were excluded using a hierarchical approach. First, we excluded reports that did not fulfill
the main inclusion criteria (n = 2,644): an original report considering drug therapy with different available drug types in non-pregnant adults of
African ancestry with uncomplicated hypertension, defined as the absence of clinical heart failure, stroke or end stage renal disease as reported
by the authors. Studies conducted exclusively in diabetics were also excluded in this step. Of the remaining studies fulfilling these main inclusion
criteria (n = 1,119), most studies were excluded in the next step (n = 982), because these were not original reports providing an explanation for
the difference in response to antihypertensive drugs between ancestry groups. As a quality and consistency check, each paper retrieved from the
search yield (n = 3,763) was categorized, per database, thus the excluded paper categories harbor duplicate reports, occurring in more than one
database. † Eligible reports thus fulfilled the inclusion criteria, and were original reports considering potential causes for the differential response
of patients of African ancestry to antihypertensive drugs used as single drug or single drug-based treatment. Included studies from the electronic
searches (n = 55) [14-68], and hand search (n = 17) [12,69-84] are described in detail in the Results section.
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headache and ankle edema [3,7].
Environmental factors Calcium antagonists manifest a
more robust blood pressure lowering effect, even in the
setting of salt intake ad libitum or a high sodium intake,
albeit at the expense of a higher drug dose [34,40,41,43].
When controlled, sodium intake in the studies varied be-
tween 40 to 100 mmol/day in low salt, and 190 to 300
mmol/day in high salt conditions [34,41,43]. With a high
salt diet and isradipine, mean systolic blood pressure(SD) in hypertensive patients of African ancestry (n = 42)
was: placebo 155.2 (19.3) vs. isradipine 139.3 (15.0) mm
Hg; a difference of −15.9; and in patients of European
ancestry (n = 92) placebo 156.9 (14.5) vs isradipine 142.1
(13.0); a difference of −14.8. With low salt, systolic blood
pressure in patients of African ancestry was placebo
142.9 (17.0) vs isradipine 135.8 (15.6); a difference of −7.1;
and in patients of European ancestry placebo 143.5 (14.6)
vs isradipine 135.9 (12.3), a difference of −7.6 [40]. In
addition, with high salt intake, the mean blood pressure
lowering effect of calcium blockers exceeded the effect of
Table 3 Summary of findings
Drug High sodium diet Pharmacokinetics Pharmacodynamics
Ca-blockers No effect* on BP lowering
efficacy [34,40,41,43]
1) Lower clearance nifedipine with
African ancestry [46]
1) Ancestry/age profiling superior to renin in predicting drug
response [38]
2) CYP3A4 genotypes sooner at BP goal†‡ 2) Ca-blockers effectively block enhanced Ca-dependent
vascular contractility, potentially mediated by high CK/low NO
with African ancestry (Figure 2) [11,12,72]
3) CYP3A5 genotypes not associated
with BP response [17,24]
3) Pharmacogenomics: ACE G12269A, C17888T, and G20037A,
and variants in the promoter region of the angiotensinogen
gene (−217G = > A and –20A = > C), were not associated
with BP response to respectively amlodipine and nifidipine
[23,26]
Diuretics No effect on BP lowering
efficacy [70]
No differences found between ancestry
groups [33]
1) No association with plasma renin levels [57,63,65,66], or
ancestry/age better predictor of response than renin [15,38]
2) Diuretics effectively block enhanced sodium retention [86],
potentially mediated by high CK in persons of African
ancestry (Figure 3) [11,12,73,87]
3) Pharmacogenomics: greater BP response with AGT 6A and
AT1R 1166A alleles (only women); [30] GNB3T allele associated
with greater BP response to HCT (only men); [32] ACE I/D,
CYP11B2 C-344 T, REN A7174G [30], STK39 [76], α-adducin
Gly460Trp, ADRBK1, and GRK5 Gln41Leu [77] not associated
with BP response
ACE-i Lower efficacy with high
salt [41]
No association of BP response with
CYP3A4 A392G, T16090C, or CYP3A5
A6986G genotypes [17]
1) Ancestry/age profiling superior to renin in predicting drug
response [38]
2) Low NO bioavailability may attenuate response (Figure 2)
[10,12,36,37,72,79-81]
3) Pharmacogenomics: ACE DD poorer response to lisinopril;
[28]§ Homozygous ACE G12269A and C17888T faster on BP
goal with ramipril than heterozygous genotypes; [23] AA
genotype 217G = > A and –20A= > C, promoter region of the
angiotensinogen gene: no significant BP decrease with
enalapril or lisinopril [26].
β-Blockers No effect on BP lowering
efficacy [70]
No consistent differences between persons
of African vs European ancestry
[44,45,52,55,56,59,61,64,67]
1) Ancestry/age profiling superior to renin in predicting drug
response [15,38,53]
2) High vascular contractility may promote peripheral
vasoconstriction with β-adrenergic blockers (Figure 2)
[3,11,12,72,88-92]
3) Pharmacogenomics: ADRB1 Arg 389/Ser 49 associates with
greater, or attenuated BP lowering; [14,20,74] GRK4 Ala142Val
faster on BP goal with metoprolol (only men); [19] GRK4
Arg65Leu and Ala486Val, GRK5 and GRK2 genotypes not
associated with BP response [18,77]
Legend: Diuretics, hydrochlorothiazide (HCT), or other diuretic drug; ACE-i, ACE inhibitors; β-blockers, β-adrenergi c blockers; BP, blood pressure; Ca-blockers,
calcium channel blockers; CK, creatine kinase. *At higher drug dose; †Pharmacodynamics unclear; ‡Only women/usual BP goal with CYP3A4 A392; or low BP goal
with CYP3A4 16090C. §Very modest effect, −0.85 mm Hg systolic (SE 0.51) and −0.50 mm Hg diastolic (SE 0.28).
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ancestry [41].
Pharmacokinetics Nifedipine clearance is reported to
be lower in persons of African ancestry, with a 150%
greater area under the plasma concentration-time curve;
and a 79% higher elimination half-life [46], but no sig-
nificant differences were found for nitrendipine [58].
Regarding genetic polymorphisms and pharmacokine-
tics, verapamil is a cytochrome CYP3A substrate, and
CYP3A5 is thought to convert cortisol to 6 b-hydro-
xycortisol in the kidney, and to be associated with salt-
sensitive hypertension. In the CYP3A5 gene, the A4G(*3) and G4A (*6) polymorphisms result in severely
decreased expression of CYP3A5 enzyme relative to a
normal functional allele (*1) [24]. These polymorphisms
were studied in the International Verapamil/trandolapril
Study (INVEST) Genetic Substudy (INVEST-GENES),
which included hypertensive subjects with coronary ar-
tery disease (n = 537; 43 of African ancestry). However,
no association was found with the antihypertensive re-
sponse to verapamil [24]. Amlodipine is also extensively
metabolized in the liver, mainly by CYP3A4 and possibly
CYP3A5. In the African-American Study of Kidney Di-
sease and Hypertension (AASK), 1,094 self-identified
African-American men and women between 18 and 70
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merular filtration rate between 20 and 65 ml/min per
1.73 m2), were randomized to amlodipine, ramipril or
metoprolol, and a mean goal arterial blood pressure
(MAP) of either 102 to 107 mm Hg (usual MAP goal)
or ≤92 mm Hg (low MAP goal) to assess the effect on
the decline in kidney function. Of these, 159 participants
were analyzed for CYP3A4 and CYP3A5 polymorphisms.
Only women randomized to a usual MAP goal, and with
an A allele at CYP3A4 A392G, were more likely to reach
a target MAP of 107 mm Hg (adjusted hazard ratio of
AA/AG compared to GG: 3.41 (95% CI: 1.20 to 9.64;
P = 0.02). Among participants randomized to a lower
MAP goal, men and women with the C allele at CYP3A4
T16090C were more likely to reach the target MAP of
107 mm Hg (adjusted hazard ratio 2.04 (95% CI 1.17 to
3.56; P = 0.01). CYP3A5 A6986G was not associated with


















Figure 2 Modulators of vascular contractility. This is a schematic repres
contraction, based on Brewster et al. [12,72]. Creatine kinase (CK) is colocali
enzyme is also colocalized with myosin light chain (LC) kinase, to rapidly su
[11,12,72,88-90]. The guanidino compounds creatine and nitric oxide (NO)
and calcium-dependent pathways are intracellular effectors of blood pressu
CK [11,12,72,88-91,93-95]. CK is high in persons of African ancestry [11,12,72
smooth muscle [11,12,72]. Vascular contractile responses can be reduced th
inhibitor (ACE-i) or nebivolol-induced NO synthesis, or through indirect inh
β-adrenergic agonists. Calcium blockers may block the entry of calcium in
(SER) [93]. β-adrenergic agonists reduce contractility mainly through inhibit
this beneficial effect, which may help explain the more frequent occurrenc
ancestry [3,92], within the context of the greater vascular contractility in th
3′,5′-(monophosphate); MLCP, myosin light chain phosphatase.Pharmacodynamics Profiling using age and ancestry
was shown to be superior to renin levels in predicting
the magnitude of the antihypertensive response to diltia-
zem [38]. Calcium blockers’ main effect is vasodilation
through a direct effect on the smooth muscle layer of re-
sistance arteries [31]. The drugs reach their effect through
a reduction of the intracellular calcium concentration
in smooth muscle, by the blocking L-subtype, voltage-
sensitive, slow calcium channels in cell membranes
and calcium outflow from the sarcoendoplasmic reticulum
[3,11,93].
The high efficacy of calcium blockers in patients of
African ancestry points to enhanced vascular smooth
muscle contractility in this group [11,12,36,37,39,72]. This
is thought to be a result of a “double jeopardy”: a lack of
NO bioavailability [10,12,31,36,37,72,80], and related high
activity of the enzyme CK [10,12,72] (Figure 2). CK fuels








entation of the main regulatory pathways of vascular smooth muscle
zed with Ca2+ ATPase and myosin ATPase, and evidence suggests the
pply these enzymes with ATP using creatine phosphate (Creatine ~ P)
have a common precursor in L-Arginine [12]. NO, RhoA/Rho kinase,
re-regulating systems that converge on metabolic processes fueled by
,73], and this is thought to lead to greater contractility of vascular
rough enhancing NO-dependent pathways, including with ACE
ibition of CK-dependent pathways, as with calcium blockers (CaB) or
the cell as well as the outflow from the sarcoendoplasmic reticulum
ion of myosin light chain kinase [91]. β-adrenergic blockers antagonize
e of blood pressure increase with β-blockers in persons of African
is population subgroup [11,12,36,37,39,72]. cGMP, guanosine cyclic
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leading to vasoconstriction [12,72]. Thus, high vascular
CK increases vascular contractility, as a final cellular step
[72]. Furthermore, the high creatine demand associated
with high creatine kinase might induce a relative lack of
L-arginine and NO [12].
Therefore, the clinical efficacy of calcium blockers in
patients of African ancestry may depend on the strong
antagonistic effect of the drug on the enhanced vascular
contractility induced by high CK and low NO (Figure 2),
but there are no clinical data yet showing this to predict
the response to calcium blockers.
Pharmacogenomic factors were studied in the AASK
study, where G12269A, C17888T and G20037A ACE
polymorphisms were not associated with blood pres-
sure lowering in participants randomized to amlodipine
(n = 159) [23]. In addition, in a study including patients of
African ancestry (n = 108), functional variants in the pro-
moter region of the angiotensinogen gene (−217G = >A
and −20A = > C), which influence the transcription of the
gene, did not predict the response to nifedipine [26].Diuretics
Clinical efficacy Diuretics are among the most effective
blood pressure lowering drugs in patients of African an-
cestry [3,7], although there is evidence that with high
baseline diastolic blood pressures, calcium blockers are
more effective [3]. Furthermore, there are concerns re-
garding metabolic side effects, including abnormal glu-
cose tolerance. This might be of particular importance
to patients of African ancestry, who have a higher risk of
developing diabetes, and often need to start treatment at
a younger age [3].Environmental factors In the Trial of Antihypertensive
Interventions and Management (TAIM), 692 partici-
pants (224 of African ancestry) aged 21 to 65 years, with
diastolic blood pressure between 90 and 100 mm Hg
and weight between 110% and 160% of ideal weight were
randomized into diet (usual, low sodium-high potassium,
weight loss) and drug (placebo, 25 mg/day chlortha-
lidone or 50 mg/day atenolol) groups resulting in nine
diet plus drug combinations. When comparing subjects
randomized to chlorthalidone (n = 24) vs placebo (n = 26)
for usual vs low-sodium diet, adding sodium restriction
(mean 100 mmol/day) to the diuretic drug did not en-
hance the blood pressure lowering effect [70].Pharmacokinetics No differences were found in bio-
availability or elimination of hydrochlorothiazide bet-
ween ancestry groups [33].Pharmacodynamics
The activity of the renin-angiotensin-aldosterone system
is thought to be inversely related to the blood pressure
response to diuretics [30]. Therefore, renin profiling was
used to predict the response to hydrochlorothiazide in
six papers, 25 mg/d in 363 participants (152 of African
ancestry), of the Pharmacogenomic Evaluation of Anti-
hypertensive Responses (PEAR) study; [15] 12.5 to 50
mg/d in a Veterans Administration study in 335 subjects
(152 of African ancestry); [38] 50 mg/d in 83 patients of
African ancestry; [57] 50 to 200 mg/d in 212 participants
(129 of African ancestry) in another Veterans Adminis-
tration study; [63] 100 mg/d in 61 patients of African
ancestry; [65] and 100 mg/d (vs furosemide 80 mg/d) in
29 patients of African ancestry [66].
Renin did not predict the response to hydrochlorothia-
zide monotherapy in four studies [57,63,65,66], nor to
furosemide (80 mg/d) [66], or spironolactone 100 to 400
mg/d [65]. In the PEAR study, the β ± SE for predic-
tion of systolic blood pressure with renin was 1.87 ± 0.90
(P = 0.04), with a relative contribution of African ances-
try of −2.12 ± 1.47 (P = 0.15); [15] and regression models
that included ancestry and age explained similar [15] or
greater [38] variation in blood pressure response than
renin.
Persons of African ancestry are reported to have a
greater tendency to retain salt [2,11,96]. This is thought
to be a primary renal mechanism, as the increased Na+
retention does not appear to be secondary to increased
production of aldosterone, deoxycorticosterone, cortisol
or 18-hydroxycortisol [82]. The main mode of action of
thiazide diuretics is to inhibit Na+Cl−-cotransporter ac-
tivity in the renal distal convoluted tubule, blocking so-
dium reabsorption across the luminal membrane. All
sodium absorption throughout the kidney is energetic-
ally and osmotically driven by the basolateral sodium
pump Na+K+ ATPase [86]. ATP generation to this so-
dium pump is supported by CK, which is tightly bound
near Na+K+ ATPase to rapidly regenerate ATP in situ
[87]. CK is thus thought to directly provide ATP for so-
dium reabsorption [11,87] (Figure 3).
The high CK activity in persons of African ancestry
has been linked to the greater tendency in this group to
retain salt [11,96]. Also, evidence was found for a more
active Na+K+2Cl
−-cotransporter in the thick ascending
limb in persons of African ancestry [71]. This might ren-
der drugs that counteract sodium retention as a mode of
action to be highly effective, but further data are needed
to substantiate how differences in kidney function in
persons of African vs European ancestry may impact re-
sponses to antihypertensive drugs.
In a pharmocogenomic approach, the association bet-
ween variation in five structural genes encoding com-
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Figure 3 Pharmacodynamics of thiazide diuretics. This is a schematic reproduction of the kidney distal convoluted tubule. Sodium retention
is driven by basolateral Na+K+ ATPase throughout the kidney [86]. Creatine kinase (CK), reported to be high in persons of African ancestry
[11,12,72,73], is tightly bound near basolateral Na+K+ ATPase, where it rapidly regenerates ATP to facilitate sodium retention [87]. Enhanced
sodium retention occurs more frequently in persons of African ancestry [96]. Thiazide diuretics counteract this effect, albeit indirectly and partly,
through inhibition of luminal Na+Cl− -cotransport.
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studied in 255 hypertensive men and women of African
and 246 European ancestry, including AGT (angioten-
sinogen) G-6A, AT1R (angiotensin II receptor, type 1)
A1166C, ACE Insertion/Deletion; CYP11B2 (aldosterone
synthase) C-344 T, and REN (renin) A7174G. Only in
women of African ancestry, but not in men or patients
of European ancestry, blood pressure lowering was
greater with an increasing number of AGT–6A alleles
(−11.3 mm Hg for GG, −18.2 mm Hg for AG and −22.2
mm Hg for AA; P = 0.03); and of AT1R 1166A alleles
(−14 mm Hg for CC, −15.6 mm Hg for AC and −22.5
mm Hg for AA; P = 0.04) [30].
The association between the response to hydrochloro-
thiazide 25 mg daily for four weeks and a polymorphism
(C825T) in exon 10 of the gene encoding the b3-subunit
of G proteins (GNB3), which potentially leads to en-
hanced sodium-proton antiport activity was assessed in
men and women of African (n = 197) and European an-
cestry (n = 190) [32]. Relative frequencies of the CC, TC
and TT genotypes of GNB3 differed significantly be-
tween groups, with the T allele significantly more fre-
quent in patients of African than in European ancestry
(76.1% versus 28.9%, P <0.01). In patients of European
ancestry, and in men, but not in women of African an-
cestry, the presence of the T allele was associated with a
greater reduction in systolic and diastolic blood pressure
with treatment, with mean declines of respectively, 10.2
and 5.9 mm Hg in CC; 13.6 and 7.8 mm Hg in TC; and
16.3 and 10.5 mm Hg in TT genotypes, accounting for
3.1% and 4.5%, respectively, of interindividual variationin the systolic and diastolic blood pressure responses to
hydrochlorothiazide [32].
The WNK-SPAK-Na+Cl−-cotransporter pathway has
been previously implicated in thiazide response, as var-
iations in WNK1 were associated with differential BP
response to hydrochlorothiazide [76]. Therefore, 195
“good” and 194 “poor” responders to hydrochlorothia-
zide 25 mg daily from the Genetic Epidemiology of
Responses to Antihypertensives study were genotyped
for approximately 100 single nucleotide polymorphisms
within 5,000 bases of STK39, with a replication sample
of 201 hydrochlorothiazide-treated hypertensives from
the PEAR study. No polymorphism was significantly as-
sociated with blood pressure response [76].
In the Genetics of Hypertension-Associated Treatment
Study (GenHAT), participants of the Antihypertensive
and Lipid-Lowering treatment to prevent Heart Attack
Trial (ALLHAT) were studied for the association bet-
ween α-adducin Gly460Trp polymorphism and blood
pressure response to chlorthalidone vs other drugs (n =
36,913; 12,696 of African ancestry). Carriers of the Trp
allele are reported to have a greater occurrence of salt-
sensitive hypertension, and blood pressure response to
diuretics was pronounced with the Trp allele, compared
to the Gly allele in European ancestry populations [25].
However, GlyGly homozygotes were significantly more
frequent in participants of African ancestry than in other
participants (82.6% vs 67.4%, P <0.01), and there was
no significant difference in systolic or diastolic blood
pressure response between Trp allele carriers and
non-carriers (systolic/diastolic reduction in Trp allele
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in non-carriers; P >0.05) [25].
Also, polymorphisms of the GRK2 gene (ADRBK1)
and GRK5 Gln41Leu, which are reported to mediate
down-regulation of β-adrenergic signaling, were studied
in 418 patients (167 of African ancestry) from the PEAR
study. The genotypes were not associated with the blood
pressure response to hydrochlorothiazide [77].
Finally, using genome wide analysis, good and poor re-
sponders to hydrochlorothiazide of African (n = 194) and
European ancestry (n = 195) were compared. Variation
in one region on chromosome 12q15 emerged to be sig-
nificantly associated with blood pressure response, but
only in subjects of African ancestry [21]. Follow-up
analysis favored YEATS4, a gene probably encoding a
transcription factor, over LYZ, encoding lysozyme, as
positional candidate genes [21]. The study has now been
replicated [83], but the biological mechanism that may
underlie the observed associations with blood pressure re-
sponse to hydrochlorothiazide is hitherto unclear.
Inhibitors of the RAAS system
ACE inhibitors
Clinical efficacy ACE inhibitors are known to induce
less blood pressure lowering in patients of African than
in European ancestry [7]. In the former, ACE inhibitors
do not differ from placebo in achieving diastolic goal
blood pressure with monotherapy [3]. The main diffe-
rence in side effects is the relatively high incidence of
angioedema with the use of ACE inhibitors in patients
of African ancestry [3].
Environmental effects High salt intake reduces the
blood pressure lowering efficacy of ACE inhibition. With
a high salt diet (190 mmol sodium/day) and enalapril
studied in 391 subjects (96 of African ancestry), systolic
blood pressure reduction in mm Hg (SD) was smaller in
patients of African, than of European ancestry (respec-
tively, placebo 156.5 (13.1) vs. enalapril 146.2 (16.4); dif-
ference −10.3 for African, and placebo 159.2 (13.4) vs
enalapril 144.2 (17.5); difference −15.0 for European an-
cestry groups).
With low salt (88 mmol sodium/day), blood pressure
was lower, but the difference persisted (African ancestry,
placebo 145.0 (16.1) vs enalapril 137.2 (19.2) difference
−7.7; European ancestry placebo 145.1 (17.1) vs enalapril
132.4 (16.2), difference −12.7) [41]. Drug efficacy of ACE
inhibitors in patients of African ancestry can thus be
modulated by controlling salt intake, or adding thiazide
diuretics to the drug regimen [8]. However, even with
low salt, the blood pressure lowering effect of ACE in-
hibitors is greater in patients of European ancestry [41].
This implies that other factors are involved in the diffe-
rence in drug response.Pharmacokinetics In the ramipril arm of the AASK
study [17], there were no associations between CYP3A4
A392G, CYP3A4 T16090C or CYP3A5 A6986G genotypes
and time to reach target mean arterial pressure among
men or women randomized to a low or usual mean arte-
rial pressure.
Pharmacodynamics The main mode of action of ACE
inhibition is well known, the drugs reduce the activity
of angiotensin converting enzyme, and eventually, an-
giotensin, aldosterone and salt retention. In addition,
ACE inhibitors promote NO synthesis in the endothe-
lium [97].
A repressed RAAS system occurs with greater fre-
quency in persons of African ancestry [2,35]. Therefore,
any drug further repressing this system could be expected
to be less effective in this population group [15,22,38,50].
However, clinical trials have produced mixed results in
whether low renin levels adequately predict an attenuated
antihypertensive response [22,38,40,50]. As with diuretics,
profiling based on age and ancestry was shown to be su-
perior to renin levels in predicting the magnitude of the
antihypertensive response to captopril [38].
Regarding the intracellular effect of ACE inhibitors,
the drugs were observed to have an ACE independent
effect [47], and partly assert their effect through NO
[97]. Thus, the lower bioavailability of NO in persons of
African ancestry [10,12,36,37,72,79,81], might contribute
to the low efficacy of ACE inhibitors. As to the cause of
low NO bioavailability, G6PD deficiency [79,80], and low
L-Arginine [69,81], associated with enhanced creatine
biosynthesis with high creatine kinase [12,72], have been
suggested.
G6PD is the first and rate-limiting enzyme of the pen-
tose phosphate pathway, thus serving as the principle
source of cellular nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH), a cofactor for NO syn-
thase. Vascular endothelial cells constitutively express
nitric oxide synthase that forms NO in the presence
of oxygen from the semi-essential amino acid L-arginine.
NO synthase binds NADPH, flavin adenine dinucleotide,
flavin mononucleotide, L-arginine, a heme moiety and
tetrahydrobiopterin. Tetrahydrobiopterin synthesis itself is
also dependent on available NADPH [80].
In line with this, G6PD deficiency, reported in up to
25% of persons of African ancestry [79], has been shown
to reduce NO bioavailability in vitro [80]. In addition,
the high creatine synthesis associated with the high cre-
atine kinase activity found in persons of African ancestry
[11,12,72,73], is thought to hamper the bioavailability of
the precursor L-arginine shared with nitric oxide syn-
thase (Figure 2). Thus, high CK has been shown to be
associated with low vascular NO bioavailability in vitro
[72], and L-Arginine was found to be low in persons of
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NO bioavailability in vivo [81]. However, there are no
clinical data yet that associate the response of ACE in-
hibitors to high CK or low NO.
Pharmacogenomic factors studied include polymor-
phisms in the ACE gene. The ACE insertion/deletion
genotype ACE DD (30% of all participants; 33% of all
participants of African ancestry, n = 13,070) had a poorer
response to lisinopril treatment than to any of the other
three drugs in the GenHAT study. However, the effect
was small, a difference of 0.85 mm Hg systolic (SE 0.51)
and 0.50 mm Hg diastolic (SE 0.28), with “similar” re-
sults reported for the subgroup analysis for patients of
African ancestry [28].
In the AASK study, participants randomized to ra-
mipril (n = 347) were genotyped at three polymorphisms
on ACE, downstream from the ACE insertion/deletion
polymorphism: G12269A, C17888T and G20037A. Only
participants with a homozygous genotype at G12269A
and C17888T, and randomized to the usual mean arterial
pressure goal (≤107 mm Hg) reached a blood pressure
goal significantly faster than those with a heterozygous
genotype (adjusted hazard ratio respectively 1.86; 95% CI
1.32 to 3.23, and 1.49; 95% CI 1.01 to 2.13, potentially due
to linkage disequilibrium with ACE I/D [23].
Finally, in a study including patients of African ancestry
(n = 77), functional variants in the promoter region of the
angiotensinogen gene (−217G = >A and −20A = >C) were
assessed. Patients with the AA genotype of the −217G= >A
variant treated with enalapril or lisinopril showed no sig-
nificant decrease in blood pressure (systolic blood
pressure + 0.84 (SD 2.89), P = 0.78; diastolic blood pres-
sure −0.47 (SD 1.74), P = 0.79); while patients with at least
one copy of the −217G allele developed respectively a 7.23
(1.55) and 5.38 (1.12) mm Hg decrease (P <0.01). Simi-
larly, in patients with the −20AA genotype no change in
blood pressure occurred, whereas in those patients with at
least one copy of the −20C allele, systolic blood pressure
decreased in response to ACE inhibitor therapy. In
line with this, patients with at least one copy of both
the −217G and the −20C allele developed substantial
decreases in blood pressure (change in mean ambulatory
blood pressure, mm Hg: SBP −14.08 +/− 3.72, P <0.01;
DBP −9.62 +/− 2.74, P <0.01) [26].
Other drugs affecting the RAAS system
Angiotensin receptor blockers are also less effective in
patients of African ancestry as compared to calcium
blockers and diuretics [3]. In one study, the mean plas-
ma concentration and elimination half-life of irbesartan
were 20 to 25% higher in persons of African than of
European ancestry, while the peak plasma concentration
was comparable between the two groups [68]. As with
ACE inhibitors, ancestry was superior to renin profilingto predict the response to candesartan [22]. Finally, the
aldosterone antagonist eplerenone was more effective
than losartan in patients of African ancestry, and equally
effective as in patients of European ancestry in one trial
[84], despite similar or lower plasma aldosterone levels re-
ported in persons of African, compared to European an-
cestry [29,84]. As stated above, renin levels did not predict
the response to spironolactone (100 to 400 mg/d) [65].
β-adrenergic blockers
Clinical efficacy The efficacy of systolic blood pressure
lowering of β-adrenergic blockade as monotherapy in
uncomplicated essential hypertension is not significantly
different from placebo in patients of African ancestry,
and some trials report significant placebo corrected in-
crease in blood pressure with β-adrenergic blockade in
this population group [3,92] The main side effects are
metabolic, including higher glucose levels [3].
Environmental factors To our knowledge, there are no
environmental factors reported that may help explain
the attenuated blood pressure lowering response of pa-
tients of African ancestry to β-adrenergic blockade. In
the TAIM study, adding sodium restriction (mean 100
mmol/day) to an atenolol regimen (usual/sodium re-
stricted diet: atenolol n = 22/29; placebo n = 26/19) did
not enhance the blood pressure lowering effect [70].
Pharmacokinetics Studies on the differences in the
pharmacokinetics of β-adrenergic blockers based on an-
cestry yielded heterogeneous results. Oral clearance of
L-propranolol was reported to be similar [56], or higher
in persons of African, than in persons of European, an-
cestry (respectively 28 ml/min/kg, SD 8; vs 21, SD 7;
P <0.05) [52], with similar, or up to 25% lower peak
plasma concentrations [52,56]. In line with this, hepatic
metabolism of propranolol via side chain oxidation,
4-hydroxylation or R-propranolol glucuronidation was
observed to be higher in persons of African than in
those of European ancestry [44]. However, propranolol
clearance after intravenous infusion (0.1 mg/kg), was
similar in one study [61]. On the other hand, around
30% higher plasma concentrations were found after 100
mg oral metoprolol in an indirect comparison between
subjects of African vs European ancestry, respectively
154 ng/ml vs 117 at t = 3 h [59], while others observed
no significant differences in plasma peak plasma concen-
trations or systemic clearance [55]. Also, metabolism of
metoprolol via CYP2D6 assessed with an oral dose of
200 mg, given to men of African and European ancestry
(10 in each group) was not significantly different [45].
Finally, pharmacokinetic studies of pindolol yielded simi-
lar results in both groups [64,67].
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of African ancestry to β-adrenergic blockers was exten-
sively studied. As renin lowering contributes to the anti-
hypertensive effect of β-adrenergic blockers, these drugs
were expected to be less effective in subjects of African
ancestry [8]. Indeed, renin correlated with the blood
pressure lowering response to atenolol 50 to 100 mg/d
in a study including 67 subjects (33 of African ancestry)
[53]. However, renin did not predict the response to
propranolol (80 to 640 mg/d) in 215 participants (132 of
African ancestry) of a Veterans Administration study
[15]. The relative contribution of renin vs African ances-
try (β ± SE) was calculated in multivariable regression
analysis, to be respectively −4.05 ± 0.84 vs −7.45 ± 1.53;
both P <0.01 [15]. Finally, in a study of 335 subjects (152
of African ancestry), therapeutic responses to atenolol
25 to 100 mg were consistent with a baseline renin pro-
file, but age-ancestry subgroup profiling was a better
predictor of response [38].
β-blockers are thought to lower blood pressure pre-
dominantly through a reduction in cardiac contractility
and heart rate. While early studies found a reduced sen-
sitivity to isoprenaline in healthy men of African ances-
try [49], reports on changes in heart rate after β-blockers
in healthy volunteers were conflicting, with either a
greater response in persons of African ancestry (to oral
propranolol 240 mg/d); [75] an attenuated response (to
intravenous propranolol up to 0.15 mg/kg [78], or meto-
prolol 50 μg/mL); [55] or no significant difference be-
tween groups (to intravenous propranolol 0.15 mg/kg)
[49]. We retrieved no studies in hypertensives.
Pharmacogenomic studies focussed on the frequency
of occurrence of the responsive β1-receptor (ADRB1)
genotype Arg 389/Ser 49 in persons of African ancestry,
which was associated with greater blood pressure lowe-
ring responses to β-adrenergic blockade in other popula-
tion subgroups [14].
In one small study, including 40 subjects (10 of African
ancestry) patients homozygous for Arg at codon 389 had
a nearly three-fold greater reduction in daytime diastolic
blood pressure (−13.3% +/− 8.4% versus −4.5% +/− 8.2%,
P <0.01) compared with those who carried the variant al-
lele, and Ser49-Arg389/Ser49-Arg389 diplotype demon-
strated a decline in blood pressure of 14.7 mm Hg versus
0.5 mm Hg in patients with the Gly49-Arg389/Ser49-
Gly389 diplotype, this was independent of ancestry [74].
In addition, Kurnik et al. studied sensitivity to β-
blockade by the attenuation of exercise-induced tachy-
cardia in 165 subjects (73 of African ancestry), and
found that heart rate reduction was greatest in the
Arg389/Arg389 group, intermediate in the heterozy-
gotes, and smallest in the Gly389/Gly389 group; this
effect was seen in both ancestry groups. Carriers of the
responsive Arg389/Ser49 haplotype, had a 27% greateradjusted reduction in heart rate at maximal exercise
(mean difference, 3.7 bpm; 95% CI, 1.2 to 6.2; P <0.01).
However, differences in sensitivity to the β1-blocker aten-
olol persisted after accounting for different distributions
of functional genetic β1-receptor variants, suggesting that
additional factors contribute to the differences found bet-
ween ancestry groups [20].
The AASK study yielded conflicting results as time to
reach the target mean arterial pressure of 107 mm Hg
with metoprolol (329 participants randomized) was not
significantly different for Ser49 or Gly49 variants. In
contrast with studies in other population subgroups, the
“hazard” ratio of reaching goal blood pressure was lower,
0.68 (95% CI 0.50 to 0.93) in individuals with at least
one ‘responsive’ Arg389 allele compared to individuals
with Gly389/Gly389 [14].
Finally, a series of pharmacogenomics studies did not
further explain why patients of African ancestry respond
less to β-adrenergic blockade. The G-protein-coupled
receptor kinase 5 (GRK5) codes for a serine/threonine
kinase that phosphorylates and desensitizes G-protein-
coupled receptors. However, in a study of 154 healthy
subjects (69 of African ancestry), GRK5 Gln41Leu poly-
morphism, present in approximately 40% of the persons
of African and 2% of individuals European of ancestry,
did not affect the response to atenolol [18]. Furthermore,
polymorphisms of the GRK2 gene (ADRBK1) and GRK5
Gln41Leu polymorphisms, studied in 418 patients (167
of African ancestry) from the PEAR study did not affect
the blood pressure response to atenolol [77]. Finally, the
polymorphisms Arg65Leu, Ala142Val, and Ala486Val of
the G protein-coupled receptor kinase gene, GRK4, were
studied in the AASK Study [19]. Only in men rando-
mized to the usual blood pressure goal (mean arterial
pressure 102 to 107 mm Hg), the adjusted “hazard” ratio
to reach goal blood pressure with metoprolol was 1.54
(95% CI 1.11 to 2.44; P <0.01) with Ala142Val. There
was no association between GRK4 polymorphisms and
blood pressure response to metoprolol in women. Thus,
despite extensive research, there is no clear pharmacoge-
nomic evidence why patients of African ancestry may
have a differential response to β-adrenergic blockade.
An important aspect of β-blocker therapy is that
inhibition of β2-mediated vasodilation by β-adrenergic
blockers may induce peripheral vasoconstriction and
blood pressure increase, thus counteracting the anti-
hypertensive effect [3,92]. (Nebivolol, a β-adrenergic
blocker that generates intravascular NO is reported to
have less vasoconstrictive effect) [16,27]. β2-adrenergic ef-
fects were addressed in the following studies. A blunted
forearm flow response was reported in subjects of African
vs European ancestry after intra-arterial infusion of isopre-
naline, a nonselective β-adrenergic agonist (respectively
10.9 (SE 1.7) with African, versus 14.9 (1.5) mL/min/dL
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in an independent study [42]. However, lymphocyte β-2-
adrenergic receptor density was found similar in subjects
of African compared to European ancestry (African,
19.2 +/− 2.2 fmol/mg protein; European, 15.2 +/− 1.4
fmol/mg protein) [54], with a lower affinity of the β2-
receptor for propranolol in persons of African ances-
try [51].
Studies on differences in intracellular cAMP produc-
tion as part of the intracellular signaling cascade after
receptor stimulation yielded conflicting results. Lower,
as well as higher, baseline and isoproterenol stimulated
cAMP levels were found in subjects of African com-
pared to European ancestry [54,62], and men of African
ancestry with the highest lymphocyte β2-adrenergic
agonists mediated cAMP production had the greatest
blood pressure increases during antagonist (metoprolol)
therapy [48].
The intracellular signaling pathway after β2-adrenergic
stimulation and cAMP production eventually leads to
inhibition of myosin light chain kinase activity and vaso-
dilation [91]. β-blockers may thus promote peripheral
vasoconstriction. Moreover, there is evidence of high
vascular smooth muscle creatine kinase in persons of
African ancestry. The enzyme CK rapidly provides ATP
for enzymes leading to vasoconstriction, including my-
osin light chain kinase [11,12,72,73]. Hence, high activity
of CK may facilitate pressor responses with β-blockers
(Figure 2), but as yet there are no clinical data to sub-
stantiate this.
α-1-adrenergic antagonists
There were only minor pharmacokinetic differences bet-
ween subjects of African (n = 6) and European ancestry
(n = 6) in trimazosin pharmacokinetics, with the latter
having a larger volume of distribution, and a longer ter-
minal elimination half-life for the metabolite, 1-hydroxy-
trimazosin [60]. Furthermore, profiling based on age and
ancestry was shown to be superior to renin levels in
predicting the magnitude of the antihypertensive res-
ponse to prazosin [38].
Discussion
Why do hypertensive patients of African ancestry ge-
nerally respond better to diuretics and calcium blockers
and less well to ACE and β-adrenergic blockade? Many
clinicians use the self-defined ancestry of a patient as a
clinical guide to select antihypertensive drugs [5], but
considerable overlap in response is known to occur be-
tween ancestry groups [3,6-8]. Therefore, many health
care workers and patients object to using ancestry as a
proxy for drug response [7,8], and it is advocated that
reduction of blood pressure and related mortality should
be achieved through individual treatment options [5,7,8].However, to reach this end, ethno-cultural and biological
differences in drug response behind the surrogate mea-
sures of ‘ancestry’ or ‘ethnicity’ need to be identified.
To our knowledge, this is the first systematic review
on environmental, pharmacokinetic and pharmacody-
namic factors that may contribute to the differential
clinical response to different types of drugs observed
in patients of African ancestry. In this paper, we also
addressed genetic variation thought to affect pharma-
cokinetic and pharmacodynamic mechanisms, of which
phase 1 and phase 2 drug metabolism and receptor func-
tion have been most extensively studied.
However, the magnitude of the effects of variation in
single candidate genes on antihypertensive drug res-
ponses appears to be very modest, accounting for only a
small percentage of total variation in response when
reported (<5%). Also, we found considerable heterogen-
eity in the direction of the effect across sex and ancestry
groups. Studies of polymorphisms may reflect inheri-
tance of a locus in linkage disequilibrium with the gene
variation. Because linkage disequilibrium is affected by
the population’s history, true associations due to linkage
disequilibrium may yield conflicting results in two separ-
ate populations [98]. No unique mutation was by itself
predictive of the therapeutic response to these drugs,
and even the combined effects of polymorphisms did
not account for enough variation in response to be clini-
cally useful.
Differences in pharmacodynamics were most consis-
tent, mainly related to the pathophysiology and clinical
characteristic of hypertension in patients of African an-
cestry. In this regard, new views have developed that ex-
pand the classical pathophysiology of patients of African
ancestry to have low renin hypertension [2,8]. Low renin
in itself does not explain the greater occurrence of hyper-
tension or the enhanced vascular contractility reported in
this group [11], and in the presented data, profiling based
on age and ancestry was equal or superior to renin in
predicting drug responses. Recent data point to a central
role for the balance between NO bioavailability and crea-
tine kinase activity [10,12,16,31,72,79-81]. The NO and
CK systems share a common precursor in L-Arginine,
and display antagonizing effects with mutual inhibition
(Figure 2). NO inhibits CK, lowers blood pressure and
promotes cardiovascular health [11,12,81,94]. High CK
activity is thought to promote salt retention and vascu-
lar contractility, with low renin as an epiphenomenon
[11,12,72]. Cytoplasmic CK is tightly bound near ATPases,
such as Na+K+ ATPase and myosin ATPase, to rapidly
transfer a phosphoryl group from creatine phosphate to
adenosine diphosphate (ADP) in situ, and generate ATP
near these ATPases, thereby facilitating ion transport
and muscle contractility [11,12,88-90]. The high crea-
tine synthesis associated with high creatine kinase activity
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bioavailability [12,72]. In line with this, CK is the main
predictor of blood pressure in the general population
[11,12,99], and of failure of antihypertensive therapy [100].
Patients of African ancestry are reported to have low NO
bioavailability [10], high CK activity [11,12,72,73], and low
L-arginine [69], with restored NO bioavailability upon
L-Arginine supplementation [81]. However, although it is
plausible that inter-individual differences in blood pres-
sure lowering efficacy of drugs could be related to the bal-
ance between NO and CK activity, with lower efficacy of
drugs that require NO synthesis (such as ACE inhibitors),
or promote CK-dependent vasoconstriction (β-adrenergic
blockers), and higher efficacy of drugs that counteract CK
(diuretics and calcium blockers), there are no further
clinical data yet to substantiate this. Hitherto, self-defined
ancestry remains the best predictor of responses to antihy-
pertensive drugs, and is shown superior to renin status.
The main strength of this study is that this is the first
systemic review, designed to assess potential causes for
the different responses of patients of African ancestry to
antihypertensive drugs, including all published papers
without language restriction, and considering salt intake,
recent development in pathophysiology and pharma-
cogenomics, as well as resulting differences in phar-
macokinetics and pharmacodynamics. Our systematic
approach reduces over-interpretation of study data, and
increases the transparency and reproducibility of the
synthesis [13].
Using this rigid methodology, the data on poten-
tial predictors of blood pressure response in patients of
African ancestry are far less conclusive than in previously
published, non-systematic overviews [6,8,98], with self-
defined ancestry remaining the best predictor of responses
to antihypertensive drugs. Although there is considerable
heterogeneity among persons of sub-Saharan African des-
cent, because of observed group differences in risk for
hypertension, the field of hypertension continues to treat
this group as a distinct biological entity [101]. We in-
cluded environmental as well as biological factors, but we
are aware that in a real world setting, differences in access
to care, clinical management and adherence to treatment
may have more impact on morbidity and mortality of pa-
tients of African ancestry than the differential response to
antihypertensive drugs [102]. Still, in our focus on the ef-
fect of drug therapy on blood pressure, we address the
most practical aspect of treatment. Lowering blood pres-
sure is the most cost-effective way to reduce the morbidity
and mortality of hypertension, and choosing highly effec-
tive drugs early in the treatment procedure helps achieve
early adequate blood pressure lowering and leads to grea-
ter adherence [5,8]. We also note that for many patients,
this would mean using initial combination therapy [5], but
there are insufficient data available to address differencesin pharmacokinetic and pharmacodynamics of combina-
tion therapy based on ancestry.Conclusions
Patients of African ancestry tend to suffer from more se-
vere hypertension, characterized by enhanced vascular
contractility and salt retaining capacity, therapy resis-
tance, and higher morbidity and mortality of the condi-
tion and its complications. Because of the need for
individual treatment options, as well as the increasing
objections to the use of ancestry as a surrogate marker
for therapeutic responses, we systematically gathered
evidence on biomarkers that may predict the response of
individual persons of African ancestry to different types
of antihypertensive drugs. However, pharmacogenomics
yield heterogeneous, insufficient evidence, and the low
renin levels found with greater frequency in patients of
African ancestry do not, or do not adequately, predict
responses to antihypertensive drugs. Finally, there are
no convincing clinical data yet of the emerging para-
digm that low NO bioavailability and associated high
cellular ATP buffer capacity predict the response to
specific antihypertensive drugs. Currently, self-identified
ethno-geographic ancestry remains the best available pre-
dictor of blood pressure lowering responses to antihyper-
tensive drugs.
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